IL5 and asthma: Currently, the severe asthma and nasal polyposis phenotype is the typical expression of eosinophilic inflammation, which implies the use of anti-IL-5 or anti-IL-5 receptor biologic therapies, as well as anti-IL-4R receptor therapy.